Novo Nordisk Pre-Tax Profit Margin 1988-2025 | NVO

Current and historical pre-tax profit margin for Novo Nordisk (NVO) from 1988 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Novo Nordisk pre-tax profit margin for the three months ending June 30, 2025 was .
Novo Nordisk Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2025-06-30 $45.48B $20.51B 45.09%
2025-03-31 $43.61B $19.02B 43.61%
2024-12-31 $42.11B $18.44B 43.80%
2024-09-30 $39.37B $17.36B 44.10%
2024-06-30 $37.44B $16.39B 43.79%
2024-03-31 $35.55B $16.28B 45.80%
2023-12-31 $33.72B $15.20B 45.07%
2023-09-30 $30.85B $13.44B 43.57%
2023-06-30 $28.44B $11.79B 41.44%
2023-03-31 $26.41B $10.64B 40.30%
2022-12-31 $25.06B $9.78B 39.03%
2022-09-30 $24.32B $9.55B 39.25%
2022-06-30 $23.81B $9.50B 39.92%
2022-03-31 $23.26B $9.52B 40.92%
2021-12-31 $22.40B $9.40B 41.96%
2021-09-30 $21.64B $9.35B 43.18%
2021-06-30 $20.85B $8.94B 42.88%
2021-03-31 $19.93B $8.51B 42.69%
2020-12-31 $19.45B $8.14B 41.86%
2020-09-30 $19.09B $7.83B 41.00%
2020-06-30 $18.74B $7.64B 40.75%
2020-03-31 $18.84B $7.49B 39.74%
2019-12-31 $18.29B $7.28B 39.79%
2019-09-30 $17.43B $6.94B 39.83%
2019-06-30 $17.25B $6.87B 39.86%
2019-03-31 $17.11B $7.05B 41.18%
2018-12-31 $17.10B $7.28B 42.58%
2018-09-30 $17.61B $7.68B 43.59%
2018-06-30 $17.49B $7.91B 45.23%
2018-03-31 $17.33B $7.78B 44.87%
2017-12-31 $16.97B $7.40B 43.58%
2017-09-30 $16.81B $7.28B 43.32%
2017-06-30 $16.73B $7.16B 42.77%
2017-03-31 $16.67B $7.20B 43.20%
2016-12-31 $16.61B $7.10B 42.76%
2016-09-30 $16.56B $7.03B 42.45%
2016-06-30 $16.43B $6.70B 40.77%
2016-03-31 $16.26B $6.35B 39.01%
2015-12-31 $16.06B $6.47B 40.29%
2015-09-30 $15.99B $6.36B 39.81%
2015-06-30 $15.95B $6.36B 39.86%
2015-03-31 $15.92B $6.45B 40.51%
2014-12-31 $15.83B $6.08B 38.39%
2014-09-30 $15.63B $6.11B 39.07%
2014-06-30 $15.31B $6.08B 39.67%
2014-03-31 $15.08B $5.94B 39.41%
2013-12-31 $14.89B $5.80B 38.93%
2013-09-30 $14.58B $5.67B 38.90%
2013-06-30 $14.27B $5.44B 38.08%
2013-03-31 $13.89B $5.11B 36.81%
2012-12-31 $13.48B $4.81B 35.64%
2012-09-30 $13.04B $4.56B 34.97%
2012-06-30 $12.80B $4.36B 34.07%
2012-03-31 $12.52B $4.20B 33.51%
2011-12-31 $12.27B $4.10B 33.40%
2011-09-30 $12.04B $3.91B 32.46%
2011-06-30 $11.85B $3.68B 31.02%
2011-03-31 $11.48B $3.43B 29.85%
2010-12-31 $11.06B $3.26B 29.49%
2010-09-30 $10.66B $3.00B 28.13%
2010-06-30 $10.24B $2.89B 28.20%
2010-03-31 $9.90B $2.81B 28.39%
2009-12-31 $9.67B $2.62B 27.09%
2009-09-30 $9.31B $2.50B 26.86%
2009-06-30 $9.10B $2.52B 27.65%
2009-03-31 $8.21B $2.49B 30.31%
2008-12-31 $8.12B $2.45B 30.19%
2008-09-30 $8.02B $2.24B 27.99%
2008-06-30 $7.69B $2.06B 26.84%
2008-03-31 $8.11B $2.18B 26.82%
2007-12-31 $7.71B $2.02B 26.19%
2007-09-30 $7.59B $2.15B 28.35%
2007-06-30 $7.24B $2.06B 28.39%
2007-03-31 $6.44B $1.68B 26.04%
2006-12-31 $6.16B $1.54B 24.98%
2006-09-30 $5.81B $1.42B 24.48%
2006-06-30 $5.73B $1.38B 24.10%
2006-03-31 $6.02B $1.34B 22.28%
2005-12-31 $5.86B $1.38B 23.46%
2005-09-30 $5.61B $1.67B 29.76%
2005-06-30 $5.36B $1.59B 29.62%
2005-03-31 $5.13B $1.52B 29.63%
2004-12-31 $4.96B $1.25B 25.12%
2004-09-30 $4.70B $0.99B 20.99%
2004-06-30 $4.46B $0.94B 21.04%
2004-03-31 $4.27B $0.92B 21.60%
2003-12-31 $4.06B $1.13B 27.74%
2003-09-30 $4.13B $1.12B 27.07%
2003-06-30 $3.97B $1.06B 26.79%
2003-03-31 $3.78B $0.97B 25.75%
2002-12-31 $3.54B $0.89B 25.02%
2002-09-30 $3.06B $0.74B 24.25%
2002-06-30 $2.91B $0.72B 24.55%
2002-03-31 $2.80B $0.67B 23.85%
2001-12-31 $2.82B $0.72B 25.42%
2001-09-30 $2.49B $0.67B 27.05%
2001-06-30 $2.43B $0.64B 26.26%
2001-03-31 $2.53B $0.66B 26.08%
2000-12-31 $2.59B $0.61B 23.44%
2000-09-30 $2.95B $1.25B 42.30%
2000-06-30 $3.09B $1.89B 61.13%
2000-03-31 $3.02B $2.44B 80.86%
1999-12-31 $2.96B $2.96B 100.00%
1999-09-30 $2.94B $2.94B 100.00%
1999-06-30 $2.82B $2.82B 100.00%
1999-03-31 $2.75B $2.75B 100.00%
1998-12-31 $2.68B $2.68B 100.00%
1998-09-30 $2.60B $2.60B 100.00%
1998-06-30 $2.65B $2.65B 100.00%
1998-03-31 $2.61B $2.61B 100.00%
1997-12-31 $2.58B $2.58B 100.00%
1997-09-30 $2.60B $0.48B 18.29%
1997-06-30 $2.53B $0.41B 16.10%
1997-03-31 $2.52B $0.39B 15.60%
1996-12-31 $2.56B $0.43B 16.95%
1996-09-30 $2.48B $2.48B 100.00%
1996-06-30 $2.45B $2.45B 100.00%
1996-03-31 $2.48B $2.48B 100.00%
1995-12-31 $2.46B $2.46B 100.00%
1995-09-30 $2.43B $2.43B 100.00%
1995-06-30 $2.36B $2.36B 100.00%
1995-03-31 $2.25B $2.25B 100.00%
1994-12-31 $2.14B $2.14B 100.00%
1994-09-30 $2.04B $2.04B 100.00%
1994-06-30 $1.96B $1.96B 100.00%
1994-03-31 $1.87B $1.87B 100.00%
1993-12-31 $1.84B $1.84B 100.00%
1993-06-30 $1.30B $1.30B 100.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $424.453B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12